Elvina Almuradova, Ambassador at European School of Oncology, shared on LinkedIn:
“Evolving HER2 Testing in the ADC Era!
New HER2-targeted ADCs (like trastuzumab deruxtecan) work even in HER2-low tumors – challenging current diagnostic standards.
Key points:
- Traditional IHC/FISH may miss HER2-low cases
- Quantitative immunofluorescence and RNA-based assays offer more precision
- Standardized, sensitive tests are needed across all solid tumors
- Accurate HER2 assessment is now essential for personalized therapy”
See article related to ADCs on OncoDaily:
Bladder Cancer Treatment: The Game-Changing Role of Antibody-Drug Conjugates (ADCs)
